Jeremy Li - Mar 23, 2023
An evaluation of imputation accuracy in a recently released open-access genomic dataset using low-pass sequencing
In this blog post, we describe some imputation performance benchmarks for a recently released haplotype reference panel from the Martin Lab comprising haplotypes from high-depth sequence data from the 1000 Genomes project and the Human Genome Diversity Project and compare them against corresponding benchmarks for the New York Genome Center's resequencing effort of the 1000 Genomes project.
Angie Mosquera, Software Engineer - Mar 21, 2023
User-customizable project configurations
We are pleased to announce a new feature that allows users to customize project configurations on the Gencove platform and provides our users with greater control over their projects.
Mamad Ahangari, Data Scientist - Mar 13, 2023
Low pass sequencing plus imputation in cattle outperforms imputation from genotyping arrays
Over the past decade, the cost of genome sequencing has significantly decreased, leading to a rise in popularity of alternative sequencing methods such as low-pass whole genome sequencing instead of genotyping arrays. To meet this demand, at Gencove, we offer a cost-effective solution for generating genome-wide information by providing low-pass whole genome sequencing plus imputation as a high-throughput alternative to genotyping arrays. Our previous research has already established that low-pass whole genome sequencing outperforms traditional genotyping arrays in terms of imputation in humans (Li et al., 2021). In this blog post, we describe the results of a recent experiment where we demonstrate that imputation using low-pass whole genome sequencing is also superior to genotyping arrays in cattle.
Joe Pickrell, CEO - Jan 01, 2023
2022 Gencove year in review
Maximillian Rozenblum, Applied Bioinformatics Engineer - Nov 10, 2022
New species: salmon
New pipeline available: salmon
Zlatko Mašek - Nov 03, 2022
Importing samples from existing projects
Samples already on the Gencove platform can now be easily reprocessed using a different project configuration.
Forest Dussault, Software Engineer - Nov 01, 2022
Processing deep sequencing data with the Gencove platform
To help move towards Gencove’s vision of ubiquitous sequencing, we’re happy to announce support for our deep whole genome sequencing (WGS) pipeline!
David Neuman, Head of Plant and Animal Genomics Sales - Aug 25, 2022
A Genotyping Platform that Changes with Your Breeding Program
Invest in a genotyping solution that changes with your breeding program. The Gencove platform ensures backward compatibility, adaptability to new markers and reference genomes, additional analyses, and continual innovation.
David Neuman, Head of Plant and Animal Genomics Sales - Aug 23, 2022
The Importance of Speed in Plant and Animal Breeding
Improve molecular breeding efficiency with a modern genotyping approach that can be set up in a few weeks plus turns your samples around quickly!
Jesse Hoff, Agrigenomics Product Manager - Jul 06, 2022
Get the Utility of Sequencing at the Cost of a Microarray
Gencove’s low-pass sequencing platform is at cost-per-sample price parity with many microarray assays across a wide range of species in both plants and animals. That makes Gencove the best choice for getting the utility of sequencing data at microarray prices.
Jesse Hoff, Agrigenomics Product Manager - Jun 15, 2022
A Modern Approach to Genotyping for Plant and Animal Breeding
There’s no question that sequencing is a powerhouse of utility for genetics in breeding. However, does it meet the requirements to become a routine tool for genomic selection in breeding programs?
Josh Setton, Head of Sales - Jun 09, 2022
Three Ways Gencove’s Low-Pass Whole Genome Sequencing is Modernizing the Drug Discovery Process
Pharmaceutical companies use Whole Exome Sequencing (WES) in their drug discovery and development process. However, R&D teams still need a comprehensive view of genomic variation outside the exome. Historically, the only way to augment WES was with arrays, but now pharma companies have an alternative - low-pass whole genome sequencing.